Syntara Limited has released a press release.
Quarterly Shareholder Update - March 2019
Filed with ASX ·
6ix hasn’t read this filing yet.
Story so far
Earlier from Syntara
- Pharmaxis Commences Phase 1 LOX Clinical Trial
- Quarterly Shareholder Update - December 2018
- Pharmaxis Announces LOXL2 Program Phase 2 Ready
- Pharmaxis announces resubmission of bronchitol nda in usa
- Pharmaxis Announces First Relaunch Sales of Aridol in USA
Later from Syntara
- US Advisory Committee Positive Recommendation on Bronchitol
- Pathway to US Bronchitol Approval Clarified in FDA Response
- Quarterly Shareholder Update - June 2019
- Pharmaxis Receives $6.2m R&D Tax Incentive
- FDA Provides Guidance on Bronchitol Approval Steps
Follow Syntara into a list and get an email when it puts out news.
Follow Syntara